117 related articles for article (PubMed ID: 36278302)
1. New insights into ruthenium(II) metallodendrimers as anticancer drug nanocarriers: from synthesis to preclinic behaviour.
Maciel D; Nunes N; Santos F; Fan Y; Li G; Shen M; Tomás H; Shi X; Rodrigues J
J Mater Chem B; 2022 Nov; 10(43):8945-8959. PubMed ID: 36278302
[TBL] [Abstract][Full Text] [Related]
2. Poly(alkylidenimine) Dendrimers Functionalized with the Organometallic Moiety [Ru(η⁵-C₅H₅)(PPh₃)₂]⁺ as Promising Drugs Against
Gouveia M; Figueira J; Jardim MG; Castro R; Tomás H; Rissanen K; Rodrigues J
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914219
[TBL] [Abstract][Full Text] [Related]
3. Cyclopentadienyl ruthenium(II) carbosilane metallodendrimers as a promising treatment against advanced prostate cancer.
Sanz Del Olmo N; Bajo AM; Ionov M; García-Gallego S; Bryszewska M; Gómez R; Ortega P; de la Mata FJ
Eur J Med Chem; 2020 Aug; 199():112414. PubMed ID: 32438200
[TBL] [Abstract][Full Text] [Related]
4. Organometallic dendrimers based on Ruthenium(II) N-heterocyclic carbenes and their implication as delivery systems of anticancer small interfering RNA.
Rodríguez-Prieto T; Michlewska S; Hołota M; Ionov M; de la Mata FJ; Cano J; Bryszewska M; Gómez R
J Inorg Biochem; 2021 Oct; 223():111540. PubMed ID: 34273717
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium metallodendrimer against triple-negative breast cancer in mice.
Michlewska S; Wójkowska D; Watala C; Skiba E; Ortega P; de la Mata FJ; Bryszewska M; Ionov M
Nanomedicine; 2023 Sep; 53():102703. PubMed ID: 37591367
[TBL] [Abstract][Full Text] [Related]
6. Regulating the anticancer properties of organometallic dendrimers using pyridylferrocene entities: synthesis, cytotoxicity and DNA binding studies.
Govender P; Riedel T; Dyson PJ; Smith GS
Dalton Trans; 2016 Jun; 45(23):9529-39. PubMed ID: 27193373
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Characterization of FITC Labelled Ruthenium Dendrimer as a Prospective Anticancer Drug.
Michlewska S; Kubczak M; Maroto-Díaz M; Sanz Del Olmo N; Ortega P; Shcharbin D; Gomez Ramirez R; Javier de la Mata F; Ionov M; Bryszewska M
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31450702
[TBL] [Abstract][Full Text] [Related]
8. Ruthenium dendrimers against acute promyelocytic leukemia:
Michlewska S; Ionov M; Maroto-Díaz M; Szwed A; Ihnatsyeu-Kachan A; Abashkin V; Dzmitruk V; Rogalska A; Denel M; Gapinska M; Shcharbin D; Gomez Ramirez R; de la Mata FJ; Bryszewska M
Future Med Chem; 2019 Jul; 11(14):1741-1756. PubMed ID: 31287722
[TBL] [Abstract][Full Text] [Related]
9. Ruthenium Dendrimers against Human Lymphoblastic Leukemia 1301 Cells.
Michlewska S; Ionov M; Szwed A; Rogalska A; Sanz Del Olmo N; Ortega P; Denel M; Jacenik D; Shcharbin D; de la Mata FJ; Bryszewska M
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32526993
[TBL] [Abstract][Full Text] [Related]
10. Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells.
Grau-Campistany A; Massaguer A; Carrion-Salip D; Barragán F; Artigas G; López-Senín P; Moreno V; Marchán V
Mol Pharm; 2013 May; 10(5):1964-76. PubMed ID: 23510087
[TBL] [Abstract][Full Text] [Related]
11. Use of Half-Generation PAMAM Dendrimers (G0.5-G3.5) with Carboxylate End-Groups to Improve the DACHPtCl
Camacho C; Tomás H; Rodrigues J
Molecules; 2021 May; 26(10):. PubMed ID: 34069054
[TBL] [Abstract][Full Text] [Related]
12. Combination of Copper Metallodendrimers with Conventional Antitumor Drugs to Combat Cancer in In Vitro Models.
Hołota M; Michlewska S; Garcia-Gallego S; Del Olmo NS; Ortega P; Bryszewska M; de la Mata FJ; Ionov M
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835489
[TBL] [Abstract][Full Text] [Related]
13. Heterofunctional ruthenium(II) carbosilane dendrons, a new class of dendritic molecules to fight against prostate cancer.
Sanz Del Olmo N; Maroto-Diaz M; Quintana S; Gómez R; Holota M; Ionov M; Bryszewska M; Carmena MJ; Ortega P; Javier de la Mata F
Eur J Med Chem; 2020 Dec; 207():112695. PubMed ID: 32882608
[TBL] [Abstract][Full Text] [Related]
14. Insight into the antitumor activity of carbosilane Cu(ii)-metallodendrimers through their interaction with biological membrane models.
Sanz Del Olmo N; Carloni R; Bajo AM; Ortega P; Fattori A; Gómez R; Ottaviani MF; García-Gallego S; Cangiotti M; de la Mata FJ
Nanoscale; 2019 Jul; 11(28):13330-13342. PubMed ID: 31271405
[TBL] [Abstract][Full Text] [Related]
15. Carbosilane metallodendrimers based on copper (II) complexes: Synthesis, EPR characterization and anticancer activity.
Sanz Del Olmo N; Maroto-Díaz M; Gómez R; Ortega P; Cangiotti M; Ottaviani MF; de la Mata FJ
J Inorg Biochem; 2017 Dec; 177():211-218. PubMed ID: 29031179
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial Effect of Carbosilane Metallodendrimers in Planktonic Cells of Gram-Positive and Gram-Negative Bacteria and
Llamazares C; Sanz Del Olmo N; Ortega P; Gómez R; Soliveri J; de la Mata FJ; García-Gallego S; Copa-Patiño JL
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31450779
[TBL] [Abstract][Full Text] [Related]
17. Elaborated study of Cu(II) carbosilane metallodendrimers bearing substituted iminopyridine moieties as antitumor agents.
Carloni R; Sanz Del Olmo N; Canonico B; Montanari M; Ciacci C; Ambrosi G; de la Mata FJ; Ottaviani MF; García-Gallego S
Eur J Med Chem; 2021 Apr; 215():113292. PubMed ID: 33631696
[TBL] [Abstract][Full Text] [Related]
18. Novel tetranuclear ruthenium(II) arene complexes showing potent cytotoxic and antimetastatic activity as well as low toxicity in vivo.
Mohamed Subarkhan MK; Ren L; Xie B; Chen C; Wang Y; Wang H
Eur J Med Chem; 2019 Oct; 179():246-256. PubMed ID: 31255925
[TBL] [Abstract][Full Text] [Related]
19. Dimetallic Ru(II) arene complexes appended on bis-salicylaldimine induce cancer cell death and suppress invasion via p53-dependent signaling.
Rahman FU; Bhatti MZ; Ali A; Duong HQ; Zhang Y; Ji X; Lin Y; Wang H; Li ZT; Zhang DW
Eur J Med Chem; 2018 Sep; 157():1480-1490. PubMed ID: 30282320
[TBL] [Abstract][Full Text] [Related]
20. Biological Effects in Cancer Cells of Mono- and Bidentate Conjugation of Cisplatin on PAMAM Dendrimers: A Comparative Study.
Camacho C; Maciel D; Tomás H; Rodrigues J
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36840012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
